Sun Pharmaceutical Industries Ratios

Sun Pharmaceutical Industries Ltd Ratios

The Sun Pharmaceutical Industries Ltd Ratios page provides a complete fundamental analysis of Sun Pharmaceutical Industries Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Sun Pharmaceutical Industries Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Sun Pharmaceutical Industries Ltd (NSE: SUNPHARMA, BSE: 524715) is currently trading at ₹1752.50, with a market capitalization of ₹4170.19B. As a major player in the Health technology sector and Pharmaceuticals: major industry, Sun Pharmaceutical Industries Ltd remains a key stock for fundamental analysis using Sun Pharmaceutical Industries Ltd Ratios.

Sun Pharmaceutical Industries Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Sun Pharmaceutical Industries Ltd P/E ratio currently stands at 38.10, making it one of the most tracked metrics in Sun Pharmaceutical Industries Ltd Ratios.

Historically, the Sun Pharmaceutical Industries Ltd P/E ratio has shown strong fluctuations:

• 2024: 38.10
• 2023: 40.60
• 2022: 27.84
• 2021: 67.07
• 2020: 49.38

The decline in Sun Pharmaceutical Industries Ltd P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The Sun Pharmaceutical Industries Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 5.77.

Historical P/B trend:

• 2024: 5.77
• 2023: 6.11
• 2022: 4.21
• 2021: 4.57

Sun Pharmaceutical Industries Ltd is trading at a premium to its book value, indicating strong market confidence.

Price to Sales Ratio (P/S)

The Sun Pharmaceutical Industries Ltd P/S ratio currently stands at 7.98, an important part of Sun Pharmaceutical Industries Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 7.98
• 2023: 8.12
• 2022: 5.37
• 2021: 5.68

A stable or declining Sun Pharmaceutical Industries Ltd P/S ratio indicates cautious market sentiment.

Sun Pharmaceutical Industries Ltd Price to Cash Flow Ratio (P/CF)

The Sun Pharmaceutical Industries Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 28.29.

Historical Sun Pharmaceutical Industries Ltd Price to Cash Flow Ratio:

• 2024: 28.29
• 2023: 30.79
• 2022: 44.42
• 2021: 24.06
• 2020: 22.99

The declining Sun Pharmaceutical Industries Ltd Price to Cash Flow Ratio suggests improving cash flow strength.

Sun Pharmaceutical Industries Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Sun Pharmaceutical Industries Ltd EV currently stands at ₹3930B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 3930B
• 2023: 3760B
• 2022: 2310B
• 2021: 2110B

Sun Pharmaceutical Industries Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.

EV/EBITDA Ratio

The Sun Pharmaceutical Industries Ltd EV/EBITDA ratio is currently 26.16, a key metric in Sun Pharmaceutical Industries Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 26.16
• 2023: 31.03
• 2022: 19.84
• 2021: 20.56

Stable Sun Pharmaceutical Industries Ltd EV/EBITDA indicates balanced valuation.

Sun Pharmaceutical Industries Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Sun Pharmaceutical Industries Ltd D/E ratio is currently 0.03, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.03
• 2023: 0.05
• 2022: 0.12
• 2021: 0.03

Sun Pharmaceutical Industries Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Sun Pharmaceutical Industries Ltd ROE currently stands at 16.09%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 16.09
• 2023: 16.01
• 2022: 16.29
• 2021: 6.93

Sun Pharmaceutical Industries Ltd maintains stable profitability levels.

Sun Pharmaceutical Industries Ltd Ratios Analysis Summary

The Sun Pharmaceutical Industries Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Sun Pharmaceutical Industries Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Sun Pharmaceutical Industries Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.